InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

InnoCare Pharma Ltd. has announced the dosing of the first patient in a global Phase II clinical trial of its TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of prurigo nodularis in China. Soficitinib is being developed for several T-cell related autoimmune disorders, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, prurigo nodularis, and urticaria. The company previously presented data from a Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis, demonstrating efficacy and a strong safety profile, at the American Academy of Dermatology (AAD) Annual Meeting. The prurigo nodularis market was valued at US$2 billion in 2024 and is projected to reach US$3 billion by 2034. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593554-en) on November 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)